Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca

Get in touch

Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.